Topics in Gastrointestinal Cancer

Boston, MA US
February 1, 2020

Description

Novel treatment options for gastrointestinal cancers and the introduction of biomarkers have resulted in considerable improvements in patient outcomes but have also increased the complexity of treatment decisions for practicing clinicians. This annual CME symposium led by Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital Cancer Center will provide attendees with the latest information on managing and treating gastrointestinal cancers, including biliary, colorectal, and pancreatic, neuroendocrine tumors, and the genomics of gastrointestinal cancers. Through lecture, panel discussion, and Q&A, this course is designed to help practitioners integrate this knowledge into their own daily practice.

Target Audience

This educational activity is designed for: medical and radiation oncologists, colon and rectal surgeons, gastroenterologists, primary care physicians, nurse practitioners, and other interested clinicians involved in the care of patients with GI cancers.

Learning Objectives

Upon completion of this course, attendees will be able to:

  1. Evaluate new surgical approaches for upper gastrointestinal malignancies and apply these procedures in routine clinical practice.
  2. Assess new management and treatment options for pancreatic, biliary and neuroendocrine tumors, and utilize these approaches in routine clinical practice to benefit patients.
  3. Appraise targeted therapy options for patients with colorectal cancer.
  4. Evaluate the role of inherited genetics through case studies and outline how to interpret and use genomics in clinical practice.
  5. Appraise and evaluate emerging approaches to radiation therapy in gastrointestinal malignancies.
  6. Interpolate and discuss the management of gastrointestinal cancers across a multidisciplinary treatment team including advanced practice providers.

 

About the Gastrointestinal Cancer Centers of Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital Cancer Center


We offer comprehensive care for patients with gastrointestinal cancers, including cancers of the colon, rectum, stomach, esophagus, pancreas, anus, bile duct (cholangiocarcinoma), liver, gallbladder, and small bowel, as well as carcinoid and islet cell malignancies.  At each cancer center, care is provided by a multidisciplinary team that includes medical oncologists; radiation oncologists; colorectal, gastrointestinal, and oncologic surgeons; and gastroenterologists, with consultative support from gastrointestinal pathologists and gastrointestinal diagnostic and interventional radiologists.

These Harvard Medical School-affiliated centers provide the latest therapies in surgery, chemotherapy, and radiation for gastrointestinal cancers.  Both centers also have active clinical research programs exploring new drug treatments and multimodality therapies.  Genetic counseling, molecular diagnostic testing, and support services, including social work, nutrition counseling, and educational and support groups are also offered.

Additional Information

Provided by: 

Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital Cancer Center and Partners HealthCare System

 

 

Course summary
Available credit: 
  • 4.25 AMA PRA Category 1 Credit™
  • 4.50 Nursing
  • 4.25 Participation
Course opens: 
11/12/2019
Course expires: 
03/04/2020
Event starts: 
02/01/2020 - 8:00am
Event ends: 
02/01/2020 - 2:00pm
Cost:
$85.00

Agenda

7:45 am

Registration Check-in and Continental Breakfast

8:15

Welcome and Introduction

Brian M. Wolpin, MD, MPH

8:20

Personalizing Therapy for Patients with Colorectal Cancer

Aparna R. Parikh, MD

8:50

Expanding Treatment Options in Neuroendocrine Tumors

Jennifer Chan, MD, MPH

9:20

New Approaches to Radiation for GI Malignancies

Harvey J. Mamon, MD, PhD

9:50

Pancreatic Cancer: Progress in Evaluation and Therapy

Brian M. Wolpin, MD, MPH

10:20

Break

10:45

Biliary Cancer: New Therapies for New Targets

Lipika Goyal, MD

11:15

Surgical Advances for Upper GI Malignancies

Jiping Wang, MD, PhD

11:45

Interpretation and Use of Genomics in Clinical Practice

Jonathan A. Nowak, MD, PhD and Marios Giannakis, MD, PhD

12:15 pm

Case Presentations from the Audience*

Moderator: Brian M. Wolpin, MD, MPH

Panelists: All presenters and Michael Casey, NP

*Participants will be encouraged to present their own problem cases for discussion by the panel and are encouraged to bring case materials.

12:50

Concluding Remarks

Brian M. Wolpin, MD, MPH

1:00 pm

Adjourn

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lunch will be served at 1:00 pm

Four Seasons Hotel
200 Boylston
Boston, MA 02116
United States

This course will be held at the Four Seasons Hotel, 200 Boylston Street, Boston MA 02116.  For directions, click here

Linking URL: http://www.fourseasons.com/boston/destination/directions_and_maps/

Brian M. Wolpin, MD, MPH; Course Director

Director, Gastrointestinal Cancer Center,
Robert T. and Judith B. Hale Chair in Pancreatic Cancer,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine,
Harvard Medical School

Brian Wolpin, MD, MPH, is Director of the Hale Family Research Center, Director of the Gastrointestinal Cancer Center, Co-Director of the Pancreas and Biliary Tumor Center, and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. He is Associate Professor of Medicine at Harvard Medical School.

Dr. Wolpin’s clinical practice involves the care of patients with gastrointestinal cancers, with a particular focus on pancreatic cancer. He has held several leadership positions related to clinical expertise, including membership on the Alliance/CALGB Gastrointestinal Cancer Committee and Pancreas Cancer Working Group, National Comprehensive Cancer Network Guidelines Committee for Pancreatic Adenocarcinoma, and Vice Chair of the National Cancer Institute Pancreas Task Force.

Dr. Wolpin’s research program is focused on understanding the factors that cause pancreatic ductal adenocarcinoma to develop and grow. These studies involve evaluation of mutations in both heritable and non-heritable genes in hundreds to thousands of subjects. His research has been funded by the National Cancer Institute, Howard Hughes Medical Institute, Lustgarten Foundation, Pancreatic Cancer Action Network, Stand Up To Cancer, ASCO Conquer Cancer Foundation, and U.S. Department of Defense.

Dr. Wolpin obtained his Doctor of Medicine from Harvard Medical School and completed a residency in internal medicine at Brigham and Women’s Hospital. He completed fellowship training in medical oncology at Dana-Farber and returned to Brigham and Women’s Hospital to serve as Chief Medical Resident. Subsequently, he received a Master of Public Health from Harvard School of Public Health.

 


Jennifer Chan, MD, MPH

Director, Program in Carcinoid and Neuroendocrine Tumors,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Dr. Chan is an Assistant Professor of Medicine at Harvard Medical School and is a Senior Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA.  She specializes in the treatment of gastrointestinal cancers and neuroendocrine tumors.  She received her medical degree from Harvard Medical School and completed her residency in internal medicine at Brigham and Women’s Hospital and fellowship training in medical oncology at Dana-Farber Cancer Institute.  She currently serves as the clinical director of the Program in Neuroendocrine and Carcinoid Tumors at the Dana-Farber/Brigham and Women's Cancer Center and has been involved in studies investigating novel therapies for neuroendocrine tumors.

 


Marios Giannakis, MD, PhD

Medical Oncologist, Gastrointestinal Cancer Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Dr. Giannakis is an Assistant Professor of Medicine at Harvard Medical School, a translational researcher and a physician in the Gastrointestinal Cancer Center in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA.  He received his medical and doctoral degrees from Washington University in Saint Louis and completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship training in medical oncology and hematology at Dana-Farber Cancer Institute.  As a physician-scientist, Dr. Giannakis specializes in the treatment of gastrointestinal cancers and is an independent investigator whose laboratory and research focuses on the pathogenesis of colorectal cancer and the development of novel targeted and immune-based therapies for patients with this disease.

 


Lipika Goyal, MD

Medical Oncologist, Division of Hematology/Oncology,
Massachusetts General Hospital Cancer Center;
Instructor in Medicine,
Harvard Medical School

Dr. Lipika Goyal completed her B.A. in neuroscience at the University of Pennsylvania and then went on to win a Rhodes Scholarship to pursue a Master of Philosophy in Development Studies at the University of Oxford.  She then attended Harvard Medical School, the Brigham and Woman’s Hospital Internal Medicine Residency, and the Dana Farber/Harvard Cancer Center Hematology/Oncology Fellowship for her medical training.  In 2013, she joined the faculty of the MGH Cancer Center as a medical oncologist in the Gastrointestinal Oncology group and currently leads research efforts in liver cancer at MGH.  Her research focuses on the development of effective therapies for cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) through translational and clinical research efforts.  She is the Principal Investigator on multiple clinical trials in hepatobiliary cancers and heads research collaborations focused on FGFR resistance in CCA, biomarker discovery, and immunotherapy in hepatobiliary cancers.  The main goal of her research is to improve outcomes for patients with these difficult cancers. She has received several grants for her research in cholangiocarcinoma including the MGH American Cancer Society Institutional Research Grant, the GI SPORE Career Development Award, the ECOR Fund for Medical Discovery Fellowship Award, the Jonathan Kraft Translational Grant, the Cholangiocarcinoma Foundation Research Grant, the V Foundation Award, and the National Institutes of Health Loan Repayment Grant for Clinical Research.

 


Harvey J. Mamon, MD, PhD

Chief, Division of Gastrointestinal Radiation Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor, Radiation Oncology,
Harvard Medical School

Dr. Mamon is an Associate Professor of Radiation Oncology, Harvard Medical School, and is the Director of Gastrointestinal Radiation Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital.  He specializes in the treatment of GI malignancies and is involved in clinical trials aimed at improving the use of radiation in treating GI cancers.  He received his medical degree from the University of Massachusetts and completed his residency in radiation oncology at the Joint Center for Radiation Therapy, where he was Chief Resident during his final year.  He currently serves as the Director of Gastrointestinal Radiation Oncology the Dana-Farber Cancer Institute/Brigham and Women’s Hospital and is the radiation oncology vice-Chair of the GI Committee of the Alliance for Clinical Trials in Oncology. Research interests include retrospective assessments of treatment approaches and outcomes, leadership roles in completed and ongoing national cooperative group clinical trials, improved tumor imaging, and prospective blood collection for analysis of circulating tumor DNA in rectal and esophageal cancer.

 


Jonathan A. Nowak, MD, PhD

Pathologist,
Brigham and Women’s Hospital;
Assistant Professor, Pathology,
Harvard Medical School

Jonathan A. Nowak, MD, PhD, is an Assistant Professor of Pathology  at Harvard Medical School and an Associate Pathologist at Brigham and Women’s Hospital.

 Dr. Nowak earned his medical degree from the Weill Medical College of Cornell University and his PhD at The Rockefeller University. He completed his residency and fellowship training at Brigham and Women’s Hospital and Harvard Medical School and is board-certified in anatomic and clinical pathology and molecular genetic pathology. As a faculty member in pathology, Jonathan helps design and interpret next generation sequencing assays for clinical tumor characterization. He also leads a newly established constitutional genetics testing service focused on hereditary cancer predisposition. Jonathan’s research is focused on the pathologic characterization of gastrointestinal cancers, chiefly colorectal and pancreatic cancer, through multiple patient cohorts under study at the Dana-Farber Cancer Institute.

 


Aparna R. Parikh, MD

Medical Oncologist, Division of Hematology/Oncology,
Massachusetts General Hospital;
Instructor in Medicine,
Harvard Medical School

Dr. Parikh was recruited to the Massachusetts General Hospital Cancer Center in the Tucker Gosnell Center for Gastrointestinal Cancer and the Termeer Center for Targeted Therapies in 2016. She completed internal medicine residency at the MGH and clinical oncology fellowship at UCSF. After fellowship, she worked briefly at Genentech while retaining clinical and teaching responsibilities at UCSF. 

At MGH, she has focus on gastrointestinal cancers, particularly colorectal and pancreatic cancer with the goal of harnessing novel strategies, including novel immunotherapy approaches to improve outcomes in these challenging cancers and is leading clinical investigator in the group.

She also leads the clinical efforts of the liquid biopsy program within Gastrointestinal Cancer Center that is a cornerstone of the GI program. The team is using liquid biopsies as a platform for understanding heterogeneous resistance mechanisms to targeted therapy and immunotherapy, tracking response to chemotherapy, targeted therapies and immunotherapy and in minimal residual disease after surgery. This work has led to a seminal paper on cell free DNA in GI Cancers, published in Nature Medicine in 2019.

She is also PI of a large, multi-institutional Stand Up 2 Cancer 400 patient trial that is using liquid biopsies to guide adjuvant colorectal cancer treatment and also leading a clinical trial comparing liquid biopsies to patient reported outcomes and tumor markers in predicting treatment response in GI cancers. She also directs the teaching curriculum for the Dana Farber Cancer Institute/Harvard Cancer Center Oncology Fellows as they do GI oncology at MGH and is actively engaged with medical student and resident. She was recently selected for the prestigious ASCO Education Scholars program.

She has received funding from the American Cancer Society, NCI GI Spore, Gateway Foundation and Stand up 2 Cancer. She also was named a Barry Scholar at MGH, a fellowship that supports rising junior faculty and most recently received the ASCO Career Development Award.

Besides a robust clinical investigator and teaching role, she has maintained a passion for cancer in the developing world after several international experiences over the years and developed and co-directs an initiative that is bringing trainees from Sub-Saharan Africa to MGH to help enhance their medical oncology training.

Dr. Parikh’s passion is caring for patients while being involved with teaching, mentoring and cutting-edge science in hopes of moving the needle for cancer patients in the United States and across the globe.

 


Jiping Wang, MD, PhD

Surgical Oncologist, Gastrointestinal Cancer Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor, Surgery,
Harvard Medical School

Dr. Jiping Wang, is Associate Professor at Harvard Medical School, and a surgical oncologist at the Dana Farber Gastrointestinal Cancer Center. He serves as Associate Director of Hepatobiliary Cancer Program at Division of Surgical Oncology, Division of Surgical Oncology, Brigham and Women's Hospital.

Professor Wang's main clinical focus is surgical treatment of sarcoma and digestive tract tumors with minimally invasive approach. Dr. Wang has been involved in cancer research for more than twenty years. He had five years’ experience in designing, conducting and reporting phase III clinical trials at National Adjuvant Breast and Bowel Project (NSABP).  He is also a member of the American Society of Clinical Oncology (ASCO) program committee and a member of the Oncology Surgery (SSO) research committee. Furthermore, he is the founding editor-in-chief of Art of Surgery and the deputy editor of NEJM YXQY.

 


Michael Casey, APRN-BC, FNP

Nurse Practitioner, Gastrointestinal Cancer Center,
Dana-Farber/Brigham and Women’s Cancer Center 

 


 

Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Partners HealthCare System designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nursing Credits

Dana-Farber Cancer Institute is approved as a provider of nursing continuing professional development by the American Nurses Association Massachusetts, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

4.5 nursing contact hours will be awarded for attending the event in its entirety and completion of an evaluation.

Available Credit

  • 4.25 AMA PRA Category 1 Credit™
  • 4.50 Nursing
  • 4.25 Participation

Price

Cost:
$85.00
Please login or register to take this course.

Thank you for your interest in this CME program.  Online registration has now closed. 

On-site registrations  will be accepted on Saturday morning, February 1st, beginning at 7:45 am.  PLEASE NOTE: Checks only for the registration payment (Cash and credit cards are NOT accepted on-site).

 

Registration Fee: non-refundable and includes course materials, continental breakfast, and lunch

  • Early Bird Rate: $75.00 through January 20, 2020
  • Regular Rate: $85.00 after January 20, 2020

 

For questions regarding registration, please contact the Partners Office of Continuing Professional Development at partnerscpd@partners.org or 857-282-2513.

For questions regarding the conference, please call 800-553-3787.

If you have any food allergies, or if you require accommodations such as an ASL interpreter, materials in an alternative format, or wheelchair access, please contact our course coordinator 10 days prior to the event at kwooten@partners.org or call 1-800-553-3787.

Required Hardware/software

The EthosCE standard install will support the two most recent stable releases of the following browsers for all public pages, both authenticated users and anonymous: Internet Explorer, Edge, Firefox, Google Chrome, Safari, Firefox. EthosCE supports these browsers by default. Other browsers may work also; however, non-listed browsers are not officially supported.